MGNX News and Press, MacroGenics Inc. From 05/28/20

- Advisory committee meeting not required; PDUFA goal date unchanged Rockville, MD, May 28, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics fo...

Rockville, MD, May 27, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced plans for a clinical study int...

Rockville, MD, May 21, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced it will host a conference call...

MacroGenics Reports Interim Clinical Data for Multiple Drug Candidates MacroGenics (MGNX) reported preliminary clinical data from the Phase 1 dose escalation and expansion clinical trial of MGD013 and from the Phase 1 dose expansion study of MGC018. The former drug candidate is aimed at tr...

Comstock Resources (NYSE: CRK )  -32%  after pricing 40M-share offering at $5/share. More news on: Comstock Resources, Inc., MacroGenics, Inc., Arvinas, Inc., Stocks on the move, , Read more ...

MacroGenics (NASDAQ: MGNX ) is down  19%  premarket on light volume on the heels of the release of abstracts on two clinical trials evaluating candidates MGD013 and MGC018 that investors appear underwhelmed with. The data will be presented at ASCO at the end of the month. More ne...

MacroGenics (NASDAQ: MGNX ) is trading down 19.5% after hours on preliminary clinical data from two investigational pipeline molecules MGD013 and MGC018. More news on: MacroGenics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

Rockville, MD, May 13, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced preliminary results from two o...

CymaBay Therapeutics (NASDAQ: CBAY ) +147%  on upgrades  and Q1 results . More news on: CymaBay Therapeutics, Inc., Novavax, Inc., NanoViricides, Inc., News on the U.S. economy Read more ...

Shares of MacroGenics (NASDAQ: MGNX)  surged today, ahead of the May 13 release of abstracts of presentations scheduled for the American Society of Clinical Oncology meeting at the end of the month. Investor optimism that the abstracts will reveal promising data for the company's early-s...